PHILIPP WERNER RAESS
Medical Practice in Madison, WI
License number
Pennsylvania MT194552
Category
Medicine
Type
Graduate Medical Trainee
Address
Address
2
Madison, WI 53711
Pennsylvania
Pennsylvania
Personal information
See more information about PHILIPP WERNER RAESS at radaris.comName
Address
Phone
3817 Paunack Ave, Madison, WI 53711
409 Eau Claire Ave, Madison, WI 53705
Professional information
Method Of Identifying Agents To Prevent Or Treat Diabetes
US Patent:
2007006, Mar 22, 2007
Filed:
Mar 21, 2006
Appl. No.:
11/385571
Inventors:
Alan Attie - Madison WI, US
Hong Lan - Edison NJ, US
Philipp Raess - Madison WI, US
Hong Lan - Edison NJ, US
Philipp Raess - Madison WI, US
International Classification:
C12Q 1/68, C12Q 1/66
US Classification:
435006000, 435008000
Abstract:
The invention provides an assay for identifying agents that can prevent and treat diabetes. Specifically, the assay is a novel tool for identifying agents that can up regulate cholecystokinin (CCK) expression in pancreatic islets of mammals. The increased expression of CCK triggers an increase in pancreatic β-cell mass and plasma insulin levels, which have been found to protect against the onset of diabetes. Also, disclosed are representative therapeutic agents identified through the assay of the invention. The methods of the invention are efficient and readily amenable to high-throughput drug screening protocols.
Methods For Modulating Cholecystokinin Expression
US Patent:
2008025, Oct 16, 2008
Filed:
Sep 19, 2006
Appl. No.:
11/523225
Inventors:
Alan D. Attie - Madison WI, US
Hong Lan - Bridgewater NJ, US
Philipp W. Raess - Madison WI, US
Hong Lan - Bridgewater NJ, US
Philipp W. Raess - Madison WI, US
International Classification:
A61K 31/711, C12Q 1/68, C12N 15/63, A61P 3/10, C12N 15/86, C12N 5/06
US Classification:
514 44, 435 6, 4353201, 435456, 435325
Abstract:
The invention provides a method for upregulating cholecystokinin (CCK) expression in mammalian pancreatic islets by administrating a CCK upregulating agent. The increased CCK expression activates islet cell proliferation triggering an increase in pancreatic β-cell mass and plasma insulin levels. Accordingly, methods to produce a replenishable supply of islet cells and to ameliorate the symptoms associated with diabetes are also disclosed.